Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.

Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?

Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.